 |
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | T-cell lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2004-01-29 00:00:00 |
| Sponsor | Mundipharma Research Limited;Cambridge Science Park, Cambridge CB4 0GW;England |
